Answers are grounded in this paper and cite their sources.
Background: Since November 2022, the highly pathogenic avian influenza (HPAI) virus subtype H5N1 clade 2.3.4.4b has caused high mortality among wild birds and poultry in Peru. Vaccines, such as recombinant Newcastle disease virus (rNDV)-vectored vaccines expressing the hemagglutinin (HA) antigen of avian influenza virus (AIV), are considered effective for preventing AI; however, the HA protein in the vaccine must be antigenically matched to the field virus to prevent mortality and virus shedding caused by AI. In this study, we developed a live rNDV-vectored vaccine expressing an HA protein with antigenic similarity to the HA of field-circulating AIV. Methods: The rNDV rLS1 strain (the parental virus) was used as a viral vector to develop the rLS1-HAOpti vaccine (an rNDV expressing the HA protein of H5N8 clade 2.3.4.4b) through reverse genetics. The immunogenicity and efficacy of the live vaccine against an HPAI H5N1 (clade 2.3.4.4b) challenge were evaluated in broiler chickens. Results: The vaccine induced a significant serum humoral response. After the H5N1 challenge, the vaccine provided protection and prevented virus shedding in most of the chickens. Conclusions: The rNDV vaccine candidate provided complete protection against mortality and clinical disease in broiler chickens challenged with H5N1 under the tested experimental conditions.
No takes yet. Share an insight, caveat, or question.
Calderón et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: